In this article, we will look at the 12 Oversold Blue Chip Stocks to Buy According to Analysts.
Oversold blue chip stocks are drawing a closer look, but not just because they have fallen. After a strong run in equities, the easier gains from multiple expansion appear harder to come by, shifting attention back to entry points, valuation discipline, and stock selection. That matters even more when large, established companies have been sold off despite analysts still holding a constructive view on the underlying business. In this kind of market, the real question is not whether weakness alone makes a stock attractive, but whether the pullback has created a better setup in blue chip names that the market may have grown too pessimistic on.
That is broadly the message in the institutional commentary. J.P. Morgan Asset Management says “High quality stocks are now priced at a discount,” adding that within U.S. markets, the quality factor is “more attractive than ever” outside unusually dislocated periods. Fidelity makes a similar point from the stock-picking side, saying “Market pullbacks can provide windows of opportunity” to buy quality stocks at “temporarily marked-down prices.” Putnam adds the large-cap angle, noting that while the S&P 500 is “more expensive than average,” “many in this cohort are trading in line with or cheaper than their historical averages.” The index may still look expensive, but parts of the blue-chip universe have already been repriced.
Against this backdrop, oversold blue chips that still carry bullish analyst views start to stand out. That brings us to the 12 Oversold Blue Chip Stocks to Buy According to Analysts.
Our Methodology
We used the Finviz screener to identify blue chip stocks with an RSI reading of less than 30, and then filtered for those offering meaningful upside based on analysts’ median price targets. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
12. Colgate-Palmolive Company (NYSE:CL)
On April 10, 2026, BofA analyst Peter Galbo lowered the price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $105 and maintained a Buy rating ahead of Q1 results. Peter Galbo said the firm updated its estimates for organic sales and FY26 EPS to reflect delayed launch timing for Optic White in North America, which impacts near-term consumption, as well as a more conservative view on gross margins given rising oil-related input costs.
On April 9, 2026, RBC Capital lowered its price target on Colgate-Palmolive Company (NYSE:CL) to $102 from $104 and maintained an Outperform rating as part of a broader Q1 preview across consumer staples. RBC said the March quarter is expected to be stable but still characterized by a sluggish top-line environment, with investor focus shifting to forward guidance amid inflationary pressures and lingering effects from the Middle East conflict, despite the recent ceasefire.
Last month, Colgate-Palmolive Company (NYSE:CL) announced that Christopher Boerner, CEO of Bristol-Myers Squibb, has been elected to its board of directors.
Colgate-Palmolive Company (NYSE:CL) manufactures and sells consumer products globally.
11. Insulet Corporation (NASDAQ:PODD)
On April 13, 2026, BTIG lowered the price target on Insulet Corporation (NASDAQ:PODD) to $320 from $380 and maintained a Buy rating as part of a broader medical technology update. BTIG said it adjusted its model following CMS’ proposed FY27 inpatient prospective payment system rule, which includes commentary and decisions on new technology add-on payments.
On April 7, 2026, Citi downgraded Insulet Corporation (NASDAQ:PODD) to Neutral from Buy with a price target of $230, down from $338, ahead of the Q1 report. Citi cited increasing competition in the patch pump market, noting that new product launches in 2027 could limit share outperformance.
Meanwhile, on April 6, 2026, Evercore ISI lowered its price target on Insulet Corporation (NASDAQ:PODD) to $240 from $340 previously and maintained an Outperform rating as part of its Q1 preview for medical technology and life science tools.
Insulet Corporation (NASDAQ:PODD) develops and sells insulin delivery systems for diabetes patients.
10. General Mills, Inc. (NYSE:GIS)
On April 13, 2026, BTIG initiated coverage of General Mills, Inc. (NYSE:GIS) with a Neutral rating and no price target. BTIG said growth fundamentals remain pressured, citing uncertainty around outcomes from the Remarkability playbook, a leveraged balance sheet, and valuation that is not significantly discounted relative to U.S. food peers, while noting potential upside from a reversion in growth.
On April 8, 2026, Wells Fargo lowered its price target on General Mills, Inc. (NYSE:GIS) to $33 from $35. Wells Fargo said it is reducing estimates across the sector ahead of earnings, with revisions driven by company-specific commodity cost assumptions and margin outlook tied to inflation trends through 2026 and 2027, with recovery expected into 2028.
Last month, General Mills, Inc. (NYSE:GIS) reported Q3 adjusted EPS of 64c versus the 73c consensus estimate, with revenue of $4.37B compared to the $4.43B consensus. CEO Jeff Harmening said the company is reaffirming fiscal 2026 guidance, noting improved competitiveness from its “Remarkability playbook,” and expects stronger organic sales trends and a return to earnings growth in Q4, with further improvement anticipated in fiscal 2027 driven by prior investments and cost efficiency initiatives.
General Mills, Inc. (NYSE:GIS) produces and sells branded consumer food products globally.
9. The J. M. Smucker Company (NYSE:SJM)
On April 13, 2026, BTIG analyst Rob Dickerson initiated coverage of The J. M. Smucker Company (NYSE:SJM) with a Buy rating and a $120 price target. Rob Dickerson said the company’s coffee segment offers underappreciated profit expansion potential and added that its broader portfolio appears better positioned amid shifting U.S. consumption trends.
On April 9, 2026, BNP Paribas lowered its price target on The J. M. Smucker Company (NYSE:SJM) to $125 from $132 and maintained an Outperform rating on the shares. The firm said U.S. packaged food valuations “look cheap relative to history,” but cautioned they are “cheap for a reason,” pointing to muted volume growth and potentially limited pricing power across the group.
Similarly, Wells Fargo analyst Chris Carey lowered the firm’s price target on The J. M. Smucker Company (NYSE:SJM) to $125 from $135 previously and kept an Overweight rating, citing sector-wide estimate reductions ahead of earnings driven by company-specific commodity cost assumptions and margin outlook tied to inflation trends through 2026 and 2027, with recovery expected into 2028.
The J. M. Smucker Company (NYSE:SJM) produces branded food and beverage products globally.
8. Conagra Brands, Inc. (NYSE:CAG)
On April 13, 2026, BTIG initiated coverage of Conagra Brands, Inc. (NYSE:CAG) with a Neutral rating and no price target. BTIG said the company is theoretically positioned to benefit from demand for healthy frozen foods and functional snacks, but expressed concern over the breadth of its U.S. portfolio, noting a long tail of smaller brands with limited investment and describing margin progression from current levels as “complicated.”
Earlier that day, Conagra announced that John Brase will become President and CEO effective June 1 and will join the board of directors. He succeeds Sean Connolly, who will step down on May 31 after more than a decade. Brase brings over 35 years of consumer goods experience and most recently served as President and COO of The J. M. Smucker Company.
On April 9, 2026, BNP Paribas downgraded Conagra to Neutral from Outperform and lowered its price target to $16 from $19. BNP Paribas said U.S. packaged food valuations “look cheap relative to history,” but argued they are “cheap for a reason,” citing muted volume growth expectations and potentially limited pricing power across the sector.
Conagra Brands, Inc. (NYSE:CAG) operates a consumer packaged food business primarily in the United States.
7. The Campbell’s Company (NASDAQ:CPB)
On April 13, 2026, BTIG analyst Rob Dickerson initiated coverage of The Campbell’s Company (NASDAQ:CPB) with a Neutral rating. Rob Dickerson cited category and brand positioning, ongoing volume deleverage, cost inflation, execution disruptions, and mix as factors limiting near-term top-line and margin recovery, adding that leverage and constrained cash flexibility support the stock’s current discounted valuation.
On April 9, 2026, BNP Paribas lowered its price target on The Campbell’s Company (NASDAQ:CPB) to $19 from $22. BNP Paribas said U.S. packaged food valuations “look cheap relative to history,” but argued they are “cheap for a reason,” pointing to muted volume growth and potentially limited pricing power across the sector.
Last month, The Campbell’s Company (NASDAQ:CPB) appointed Joshua Levine as Chief Investor Relations Officer, reporting to CFO Todd Cunfer. The company said Levine brings extensive experience across finance, capital markets, and the food industry, with a track record of building investor relationships.
The Campbell’s Company (NASDAQ:CPB) produces and markets food and beverage products globally.
6. Abbott Laboratories (NYSE:ABT)
On April 10, Reuters reported that a jury in Chicago ruled that Abbott Laboratories (NYSE:ABT) must pay $70 million in damages to a group of families. The families had accused the company of failing to warn that its formula for premature infants could cause a potentially deadly bowel disease, according to a company spokesperson.
The decision followed a lengthy trial. It is one of many cases, with hundreds of lawsuits claiming that Abbott’s cow milk-based formula products for preterm infants are linked to necrotizing enterocolitis, or NEC. In this case, four families combined their lawsuits into a single trial. The jury found the company liable on April 9 and awarded $53 million in compensatory damages to the families, the spokesperson said. They returned the next day to consider punitive damages and awarded an additional $17 million.
On April 8, 2026, Barclays raised its price target on Abbott to $144 from $142 and maintained an Overweight rating after updating its model to reflect the Exact Sciences acquisition. Meanwhile, Evercore ISI analyst Vijay Kumar lowered the firm’s price target to $134 from $138 and kept an Outperform rating as part of its Q1 preview for medical technology and life science tools.
Last month, Abbott and Flatiron Health announced the integration of Abbott’s Precision Oncology portfolio into Flatiron’s OncoEMR platform, enabling providers to order tests and receive results directly within their clinical workflow. The integration includes tests such as Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, and Riskguard, and expands access across Flatiron’s network of more than 1,600 cancer care centers and 4,700 providers.
Abbott Laboratories (NYSE:ABT) develops and sells healthcare products globally.
While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Oversold Blue Chip Stocks to Buy According to Analysts.
Disclosure: None. Follow Insider Monkey on Google News.
